Compare Gilead Sciences, Inc. (GILD) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kimberly Clark Corp — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Kimberly Clark Corp trades at $97.72 (market cap $32.51B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kimberly Clark Corp for 93 Days on average.
| GILD | KMB | |
|---|---|---|
Market Cap | $182.40B | $32.51B |
Volume | 4,469,821 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $121.44 |
52-Week Low | $116.74 | $93.05 |
Typical Hold Time | 111 Days | 93 Days |
Enterprise Value | $205.46B | $38.07B |
Dividend Yield | 2.23% | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Kimberly-Clark (KMB) trades at $96.48, down 0.3% on the day, showing bearish technical signals with recent price weakness. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, while analyst consensus remains cautiously optimistic with a $117.25 price target. Key developments include executive transitions and ongoing Kenvue acquisition negotiations with EU regulators.
KMB presents a mixed investment case with attractive 5.16% dividend yield and 54-year dividend growth streak, but faces execution risks from the Kenvue acquisition and cash flow pressures. The stock trades below analyst targets with bearish technical momentum, requiring careful monitoring of merger integration and cash flow sustainability for dividend investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
